Core E: Prevention Science Core (PSC)Basic purposes of the core will be: 1) to develop and coordinate Prevention Science activities throughout theCFAR institutions, including Tufts and Brown Universities and the Fenway Community Health Center; 2) toexpand and coordinate CFAR Prevention Science activities in collaborating institutions in resource-restrictedcountries; 3) to guide behavioral science activities throughout the CFAR; and 4) to assist in the training oflocal CFAR investigators and international Fogarty trainees in diagnostic techniques appropriate to the earlydiagnosis of HIV infection in both domestic and resource-restricted environments.Staff of the core will include Core Director Kenneth H. Mayer, MD, Professor of Medicine and CommunityHealth at Brown Medical School. This core provides all Prevention and Education activities in this CFARincluding the Fogarty AIDS International Research Training Program, HVTN, HPTN, and other ClinicalImmunology Laboratory microbicide research. Dr. Mayer will provide advice on the prevention sciencerelatedanalysis performed in the Clinical Immunology Laboratory, which is directed by the RetrovirologyServices Core (Core H). The laboratory is available for CFAR prevention science investigators to do assayson specimens from high-risk populations to obtain estimates of HIV incidence (e.g., measurement ofantibody by the BED Capture assay, HIV RNA pooling, dried blot spot assays, and other serodiagnosticassays). Dr. Mayer will convene regular meetings of the Prevention Science Investigators to plan jointprojects and review data generated by CFAR Prevention Science investigators. Lola Wright, theadministrative coordinator of the PSC, will be responsible for meeting logistics and clerical/administrativesupport for Core investigators, as well as the focal person for information dissemination. Robert Ducharmeis the PSC Research Associate who will assist investigators in developing new protocols, conductingqualitative interviews in hard-to-reach populations, and in collecting quantitative data for CFAR pilot studies,and performing HIV rapid testing for hard-to-reach populations. The Prevention Science Core will alsocoordinate the research collaborations with Fenway Community Health, which serves as a major componentof the CFAR Prevention Science activities. Current HPTN and HVTN activities in the CFAR include bilateralcollaborations between the Miriam Hospital and Fenway Community Health, including joint initiatives incommunity education and training in GCP for the conduct of NIH-funded clinical trials. The PSC will beresponsible for the coordination of local prevention and behavioral research initiatives emanating from thenew Clinical Trials Unit initiatives (i.e. HPTN, HVTN, MTN).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI042853-10
Application #
7278955
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
10
Fiscal Year
2007
Total Cost
$182,266
Indirect Cost
Name
Miriam Hospital
Department
Type
DUNS #
063902704
City
Providence
State
RI
Country
United States
Zip Code
02906
Murphy, Matthew; Berns, Abby L; Bandyopadhyay, Utpala et al. (2018) Varicella in the prison setting: A report of three outbreaks in Rhode Island and a review of the literature. Vaccine 36:5651-5656
Sam, Soya S; Caliendo, Angela M; Ingersoll, Jessica et al. (2018) Evaluation of Performance Characteristics of Panther Fusion Assays for Detection of Respiratory Viruses from Nasopharyngeal and Lower Respiratory Tract Specimens. J Clin Microbiol 56:
Peloquin, Charles A; Phillips, Patrick P J; Mitnick, Carole D et al. (2018) Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother 62:
Linas, Benjamin P; Nolen, Shayla (2018) A Guide to the Economics of Hepatitis C Virus Cure in 2017. Infect Dis Clin North Am 32:447-459
Carroll, Jennifer J; Rich, Josiah D; Green, Traci C (2018) The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible. J Addict Med 12:459-465
Coleman, Sharon M; Gnatienko, Natalia; Lloyd-Travaglini, Christine A et al. (2018) False-positive HIV diagnoses: lessons from Ugandan and Russian research cohorts. HIV Clin Trials 19:15-22
Sherman, Kenneth E; Rouster, Susan D; Kong, Ling X et al. (2018) Zika Virus Exposure in an HIV-Infected Cohort in Ghana. J Acquir Immune Defic Syndr 78:e35-e38
N'Guessan, Kombo F; Boyce, Ceejay; Kwara, Awewura et al. (2018) Human pegivirus (HPgV) infection in Ghanaians co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Virus Genes 54:361-367
Freiman, J Morgan; Jacobson, Karen R; Muyindike, Winnie R et al. (2018) Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 77:405-412
Chan, Philip A; Crowley, Christina; Rose, Jennifer S et al. (2018) A Network Analysis of Sexually Transmitted Diseases and Online Hookup Sites Among Men Who Have Sex With Men. Sex Transm Dis 45:462-468

Showing the most recent 10 out of 806 publications